X0202 SCHEDULE 13G/A 0000902664-26-001060 0001784547 XXXXXXXX LIVE 1 Ordinary Shares, no par value per share 03/31/2026 0001671502 Quoin Pharmaceuticals, Ltd. 74907L409 23 HATA'AS STREET KFAR SABA L3 44425 Rule 13d-1(b) Woodline Partners LP DE 2785370.00 0.00 2785370.00 0.00 2785370.00 N 4.4 IA PN Quoin Pharmaceuticals, Ltd. 42127 Pleasant Forest Court, Ashburn, VA 20148-7349 This statement is filed by Woodline Partners LP ("Woodline Partners" or the "Reporting Person"), a Delaware limited partnership, and the investment adviser to Woodline Master Fund LP (the "Woodline Fund"), with respect to the ordinary shares, no par value per share ("Ordinary Shares"), of Quoin Pharmaceuticals, Ltd. (the "Company") represented by American Depositary Shares ("ADSs") directly held by the Woodline Fund. There is no CUSIP number assigned to the Ordinary Shares. The CUSIP number 74907L409 has been assigned to the ADSs of the Company, which are quoted on The Nasdaq Capital Market under the symbol "QNRX." Each ADS represents thirty-five Ordinary Shares. The filing of this statement should not be construed as an admission that any of the foregoing persons or the Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the Ordinary Shares reported herein. The address of the business office of Woodline Partners is 4 Embarcadero Center, Suite 3450, San Francisco, CA 94111. Woodline Partners is a Delaware limited partnership. N IA The information required by Item 4(a) is set forth in Row 9 of the cover page for the Reporting Person and is incorporated herein by reference. The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 63,126,930 Ordinary Shares outstanding as of March 23, 2026, as reported in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Securities and Exchange Commission on March 26, 2026. 4.4% The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for the Reporting Person and is incorporated herein by reference. The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for the Reporting Person and is incorporated herein by reference. The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for the Reporting Person and is incorporated herein by reference. The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for the Reporting Person and is incorporated herein by reference. N Y N See Item 2(a). Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Woodline Partners LP /s/ Erin Mullen 05/15/2026